To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
9 Current news of Affimed Therapeutics
rss
Affimed enrolls first patients in Phase I Hodgkin's Lymphoma Study
11-17-2010
Affimed Therapeutics AG announced that the first patients with Hodgkin's Lymphoma have been treated with the AFM13 TandAb® antibody in a Phase I clinical study. The Phase I repeat dose escalation study will enroll approximately 40 Hodgkin's Lymphoma patients across two centers in Europe and ...
Affimed Therapeutics AG expands clinical development team
03-10-2010
In preparation for the clinical entry of its first product candidate Affimed Therapeutics AG expands its development team with an experienced expert. Effective immediately, Dr Christian Hucke takes over responsibility for planning and implementation of the clinical development programs at ...
Affimed joins the Molecular Imaging Technology Initiative
BMBF awards Affimed a funding grant of €550K
02-11-2009
Affimed Therapeutics AG announced the start of a collaboration project with Bayer Schering Pharma AG, the German Cancer Research Center (DKFZ) and other partners within the Molecular Imaging Technology Initiative launched by the German Federal Ministry of Education and Research (“BMBF”). ...
Affimed appoints Chief Business Officer
06-10-2008
Affimed Therapeutics AG announced that it has appointed Volker Lang, Ph.D., as its Chief Business Officer. Dr. Lang joins Affimed from Scil Technology where he was Vice President of Corporate Development. At Scil Technology, he was responsible for the commercial development of a portfolio of ...
Affimed validates antibody target for cancer metastasis
05-14-2008
Affimed Therapeutics AG announced that a collaboration with Dr. Stefan Weiss at the Institute of Biochemistry of the Ludwig Maximilian University in Munich has strongly validated a target for cancer metastases amenable to the development of antibodies or other therapeutic interventions. The ...
Affimed's fully human anti-thrombosis antibody shows in vivo efficacy with reduced side effects
12-07-2006
Affimed Therapeutics AG announced that preclinical proof of concept has been established for its anti-thrombosis product candidate. According to the company, Affimed's fully human antibody predominantly binds to the activated form of a receptor (GPIIb/IIIa) that plays a major role in the ...
XOMA and Affimed Sign Antibody Cross-License and Collaboration Agreement
10-05-2006
XOMA Ltd. and Affimed Therapeutics AG have signed a cross-license and collaboration agreement for antibody-related technologies. Financial terms were not disclosed. The agreement provides XOMA with a license under Affimed's antibody library patents for antibody discovery purposes, as well ...
Affimed Therapeutics and Biopharma Unit of Syngenta Enter Into Agreement to Co-develop Tandabs
11-08-2004
Heidelberg. Affimed Therapeutics AG, a Heidelberg, Germany-based drug development company, has signed a partnership agreement with the biopharmaceutical unit of Syngenta AG of Basel, Switzerland to co-develop one of Affimed's proprietary Tandab antibodies. Tandabs recruit the body's immune ...
Affimed and Dyax Cross-License Antibody Technologies
08-15-2003
Affimed Therapeutics AG and Dyax Corp. announced today that they have entered into a cross-licensing agreement for phage display technologies. Financial terms were not disclosed. The Affimed licensed patents consist of two issued U.S. patents with broad claims. They cover the generation of ...
Page 1 From 1
